ATE264100T1 - Zusammensetzung und verfahren - Google Patents
Zusammensetzung und verfahrenInfo
- Publication number
- ATE264100T1 ATE264100T1 AT99967619T AT99967619T ATE264100T1 AT E264100 T1 ATE264100 T1 AT E264100T1 AT 99967619 T AT99967619 T AT 99967619T AT 99967619 T AT99967619 T AT 99967619T AT E264100 T1 ATE264100 T1 AT E264100T1
- Authority
- AT
- Austria
- Prior art keywords
- ccr5
- receptor
- treatment
- antagonists
- copd
- Prior art date
Links
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 abstract 4
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 abstract 4
- 102000004274 CCR5 Receptors Human genes 0.000 abstract 2
- 108010017088 CCR5 Receptors Proteins 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- ZVSKZLHKADLHSD-UHFFFAOYSA-N benzanilide Chemical class C=1C=CC=CC=1C(=O)NC1=CC=CC=C1 ZVSKZLHKADLHSD-UHFFFAOYSA-N 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000012657 Atopic disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000031886 HIV Infections Diseases 0.000 abstract 1
- 208000037357 HIV infectious disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000007115 recruitment Effects 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 201000000306 sarcoidosis Diseases 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11423998P | 1998-12-30 | 1998-12-30 | |
| US12801099P | 1999-04-06 | 1999-04-06 | |
| PCT/US1999/030888 WO2000040239A1 (en) | 1998-12-30 | 1999-12-28 | Compounds and methods |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE264100T1 true ATE264100T1 (de) | 2004-04-15 |
Family
ID=26811962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99967619T ATE264100T1 (de) | 1998-12-30 | 1999-12-28 | Zusammensetzung und verfahren |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1140072B1 (de) |
| JP (1) | JP2002534383A (de) |
| AT (1) | ATE264100T1 (de) |
| DE (1) | DE69916496T2 (de) |
| ES (1) | ES2219104T3 (de) |
| WO (1) | WO2000040239A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7132546B2 (en) | 2000-12-22 | 2006-11-07 | Ishihara Sangyo Kaisha, Ltd. | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
| JP4083422B2 (ja) * | 2000-12-22 | 2008-04-30 | 石原産業株式会社 | アニリン誘導体またはその塩ならびにそれらを含有するサイトカイン産生抑制剤 |
| WO2004080966A1 (ja) | 2003-03-14 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| JP4710606B2 (ja) | 2003-04-18 | 2011-06-29 | 小野薬品工業株式会社 | スピロピペリジン化合物およびその医薬用途 |
| EP1720826A4 (de) * | 2004-03-02 | 2007-10-31 | Neurogen Corp | Heteroalkylsubstituierte biphenyl-4-carbonsäurearylamidanaloga |
| NZ553696A (en) | 2004-09-13 | 2010-02-26 | Ono Pharmaceutical Co | Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient |
| US20110052612A1 (en) | 2005-05-31 | 2011-03-03 | Ono Pharmaceutical Co., Ltd. | Spiropiperidine compound and medicinal use thereof |
| EP1942108B1 (de) | 2005-10-28 | 2013-09-04 | Ono Pharmaceutical Co., Ltd. | Eine basische gruppe enthaltende verbindung und anwendung davon |
| EP1961744B1 (de) | 2005-11-18 | 2013-04-17 | Ono Pharmaceutical Co., Ltd. | Verbindung mit basischen gruppen und deren verwendung |
| WO2007105637A1 (ja) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| JP5257068B2 (ja) | 2006-05-16 | 2013-08-07 | 小野薬品工業株式会社 | 保護されていてもよい酸性基を含有する化合物およびその用途 |
| EP2055705A4 (de) | 2006-07-31 | 2014-08-20 | Ono Pharmaceutical Co | Verbindung mit einer über eine spiro-bindung daran gebundenen cyclischen gruppe und anwendung davon |
| WO2010129351A1 (en) | 2009-04-28 | 2010-11-11 | Schepens Eye Research Institute | Method to identify and treat age-related macular degeneration |
| WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4091097A (en) * | 1973-04-20 | 1978-05-23 | Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai | Treatment of elevated histamine and uric acid levels |
| ZA985542B (en) * | 1997-07-03 | 1999-04-07 | Smithkline Beecham Corp | Substituted benzanilides as CCR5 receptor ligands antiinflammatory agents and antiviral agents |
-
1999
- 1999-12-28 AT AT99967619T patent/ATE264100T1/de not_active IP Right Cessation
- 1999-12-28 ES ES99967619T patent/ES2219104T3/es not_active Expired - Lifetime
- 1999-12-28 DE DE69916496T patent/DE69916496T2/de not_active Expired - Lifetime
- 1999-12-28 WO PCT/US1999/030888 patent/WO2000040239A1/en not_active Ceased
- 1999-12-28 EP EP99967619A patent/EP1140072B1/de not_active Expired - Lifetime
- 1999-12-28 JP JP2000591996A patent/JP2002534383A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1140072A1 (de) | 2001-10-10 |
| EP1140072A4 (de) | 2003-04-16 |
| WO2000040239A1 (en) | 2000-07-13 |
| ES2219104T3 (es) | 2004-11-16 |
| EP1140072B1 (de) | 2004-04-14 |
| DE69916496T2 (de) | 2004-09-02 |
| DE69916496D1 (de) | 2004-05-19 |
| JP2002534383A (ja) | 2002-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL133730A0 (en) | Compounds and methods substituted benzanilides as ccr5 ligands | |
| WO2004011427A3 (en) | Substituted benzanilides as modulators of the ccr5 receptor | |
| WO2004010943A3 (en) | Substituted benzanilides as modulators of the ccr5 receptor | |
| DE69916496D1 (de) | Zusammensetzung und verfahren | |
| WO2004010942A3 (en) | Substituted heterocyclic compounds as modulators of the ccr5 receptor | |
| AR013669A1 (es) | Compuestos y metodos | |
| EP1156801A4 (de) | Zusammensetzungen und verfahren | |
| DK1718649T3 (da) | Imidazo[1,2-c]pyrimidinyleddikesyrederivater | |
| Wei et al. | Resolution of cutaneous sarcoidosis after Janus kinase inhibitor therapy for concomitant polycythemia vera | |
| MY147984A (en) | Pyrimidine derivatives | |
| AU4455896A (en) | A chemokine receptor able to bind to mcp-1, mip-1 alpha and/or rantes. its uses | |
| TW200608995A (en) | Antagonizing interleukin-21 receptor activity | |
| DOP2003000638A (es) | Tetrahidropiridopiridinicos de la actividad de receptores de quimiocina | |
| ES2128544T3 (es) | Pirrolopirimidinas como antagonistas del crf. | |
| BR0009869A (pt) | Método para inibir a produção e/ou secreção de citoquina, e, composição farmacêutica | |
| JOP20170136B1 (ar) | ستخدام مركبات إندازول مستبدل في الموقع 2 للمعالجة والوقاية من اضطرابات المناعة الذاتية | |
| ATE422496T1 (de) | Als medikamente für die behandlung von autoimmunerkrankungen geeignete substituierte pyridoä2,3-düpyrimidinderivate | |
| Maggi et al. | T cell subpopulations in juvenile idiopathic arthritis and their modifications after biotherapies | |
| WO2002034760A3 (en) | Compounds and methods | |
| WO2023086428A3 (en) | Novel modulators of the aryl hydrocarbon receptor and methods of use thereof | |
| MX2007000046A (es) | Compuestos, composiciones y metodos de imidazolo relacionados para su uso. | |
| Chacur et al. | Bradykinin is involved in hyperalgesia induced by Bothrops jararaca venom | |
| ES2138366T3 (es) | Indol carbamatos como antagonistas de leucotrienos. | |
| TW200745087A (en) | CCR5 antagonists useful for treating HIV | |
| WO2025006568A3 (en) | Mk2 inhibitors and methods of making and using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |